ArticleKidney international reports2022
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04034992 (An Observational Study Collecting Real-world Data on Patients With Chronic Kidney Disease to Assess), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Observational Study Collecting Real-world Data on Patients With Chronic Kidney Disease to Assess: Early Treatment Experience, Treatment Patterns, Treatment Effectiveness, Patient Outcomes and Patient Quality of Life Through Prospective and Retrospective Data Capture
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Challenges and strategies for managing early-to-moderate chronic kidney disease in primary care: A systematic integrative review in high-income countries.The European journal of general practice · 2026Pooled it
- Kidney dysfunction and its associated factors among people living with HIV on antiretroviral therapy in rural Rwanda: a cross-sectional study.BMC infectious diseases · 2026Article
- Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease.European journal of heart failure · 2025Review
- Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.Advances in therapy · 2025Review
- Pediatric Chronic Kidney Disease: Mind the Gap Between Reality and Expectations.Children (Basel, Switzerland) · 2025Review
- Effectiveness of a systematic home-based albuminuria screening programme to detect chronic kidney disease in high-risk individuals in primary care (SALINE): a cross-sectional screening study.EClinicalMedicine · 2025Article
- Obstacles and Opportunities for Albuminuria Testing On the Basis of the Perspective of Primary Care: A Qualitative Study.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Enhancing the use of sodium-glucose cotransporter-2 inhibitors in type-2 diabetic patients with chronic kidney disease, through a key performance indicator program.Qatar medical journal · 2025Article
- Sigma-1 Receptor Rescues Autophagy Through AMPK/mTOR Signaling Pathway in Sepsis-Induced Acute Kidney Injury.International journal of general medicine · 2025Article
- Association between composite dietary antioxidant index and increased urinary albumin excretion: a population-based study.Frontiers in nutrition · 2025Article
- A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Projecting the Population Level Burden of CKD Progression According to Urine Albumin-to-Creatinine Ratio Categories.Kidney international reports · 2024Article
- Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.Kidney medicine · 2024Article
- Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.Advances in therapy · 2024Article
- Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.Kidney international reports · 2024Article
- Article
- Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.Advances in therapy · 2024Article
- General practitioners' representation of early-stage CKD is a barrier to adequate management and patient empowerment: a phenomenological study.Journal of nephrology · 2024Article
- The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.American journal of nephrology · 2024Observational
- Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis.BMJ medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines classify chronic kidney disease (CKD) risk or prognosis using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). We assessed patient characteristics and outcomes according to the KDIGO classification, using data from DISCOVER CKD (NCT04034992). Methods: Data were extracted from the US integrated Limited Claims and Electronic Health Record Dataset and TriNetX databases, and the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office for National Statistics databases. Eligible patients were aged ≥18 years with CKD, and identified by 2 consecutive eGFR measures (5 to <75 ml/min/1.73 m Results: Across databases, only 8.6% of patients with 2 eGFR measures had ≥1 UACR measures. Among 123,807 eligible patients, prevalence of heart failure, hypertension, and type 2 diabetes increased with increasing albuminuria. Incidence rates of mortality and adverse cardiovascular and renal outcomes increased with declining baseline eGFR, and particularly with increasing albuminuria. Median number of eGFR and UACR tests per year post-index ranged from 1.6 to 2.5 and 0.5 to 0.6, respectively, across databases; there was no clear increase in UACR testing frequency following the KDIGO 2012 guidelines. Conclusion: Albuminuria monitoring is critical for optimal risk stratification in CKD, and our findings highlight an imperative for more regular UACR testing in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.